Next day disclosure return
Filed with HKEX · Stock code 1177 · · 6 pages · English
Sino Biopharmaceutical Limited on 6ix
Earlier from Sino Biopharmaceutical
- Voluntary announcement - completion of all subjects enrollment in the phase iii registrational clinical trial of TQC3721 inhalation suspension "PDE3/4 inhibitor"
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
- Voluntary announcement - enter into strategic biosimilars partnership with STADA
- Notification letter and request form for non-registered shareholders
- Notification letter and reply form for registered shareholders
Later from Sino Biopharmaceutical
- Voluntary announcement - latest research results on tq-A3334 "TLR7 agonist" and bepirovirsen "aso" to be presented at 2026 aasld
- Voluntary announcement - completion of all participants enrollment in the phase iii registrational clinical trial of TQC2731 injection "tslp monoclonal antibody" for chronic sinusitis with nasal polyps
- Voluntary announcement - data from two clinical studies of TQB2102 "HER2 biparatopic adc" presented at 2026 esmo
- Voluntary announcement - tq-A3334 "TLR7 agonist" and TQA3605 "core protein allosteric modulator" granted breakthrough therapy designation by cde
- Monthly return of equity issuer on movements in securities for the month ended 31 October 2026
Follow Sino Biopharmaceutical into a list and get an email when it puts out news.
Follow Sino Biopharmaceutical